Hiroji Iwata
Impact in
- Oncology top 0.02%
- HER2/EGFR in Cancer Research
- Cancer Immunotherapy and Biomarkers
- Cancer-related Molecular Pathways
- Cancer Treatment and Pharmacology
- Cancer Cells and Metastasis
- Cancer Research top 0.05%
- Breast Cancer Treatment Studies
- Cancer Genomics and Diagnostics
Papers in
- Oncology 359
- HER2/EGFR in Cancer Research 165
- Cancer Treatment and Pharmacology 134
- Cancer Immunotherapy and Biomarkers 36
- Cancer Research 172
- Breast Cancer Treatment Studies 146
- Co-authors
- Sherene LoiHope S. RugoCarlos H. BarriosSeock‐Ah ImPeter SchmidSylvia AdamsLuciana MolineroEric P. Winer
- Journals
- Journal of Clinical Oncology (69 papers)Breast Cancer (65 papers)Annals of Oncology (50 papers)Cancer Research (45 papers)Breast Cancer Research and Treatment (31 papers)
- Partner nations
- JapanUnited StatesFrance
In The Last Decade
Hiroji Iwata
495 papers receiving 23.4k citations
Hit Papers
Peers
Comparison fields: 5 of 162
- Oncology 16.7k
- Cancer Research 7.1k
- Pulmonary and Respiratory Medicine 9.6k
- Genetics 2.0k
- Immunology 2.5k
Countries citing papers authored by Hiroji Iwata
This map shows the geographic impact of Hiroji Iwata's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hiroji Iwata with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hiroji Iwata more than expected).
Fields of papers citing papers by Hiroji Iwata
This network shows the impact of papers produced by Hiroji Iwata. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hiroji Iwata. The network helps show where Hiroji Iwata may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Hiroji Iwata, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 1 | |
| 2 | 2024 | 2 | |
| 3 | 2024 | 0 | |
| 4 | 2024 | 1 | |
| 5 | 2024 | 1 | |
| 6 | 2023 | 28 | |
| 7 | 2023 | 1 | |
| 8 | 2023 | 2 | |
| 9 | 2023 | 7 | |
| 10 | 2023 | 2 | |
| 11 | 2022 | 3 | |
| 12 | 2021 | 7 | |
| 13 | Alpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancer Hit paper breakdown → | 2019 | 1565 |
| 14 | [A Phase I Combination Dose-Escalation Study of Eribulin Mesylate and Gemcitabine in Japanese Patients with Metastatic Breast Cancer]. | 2018 | 1 |
| 15 | 2017 | 55 | |
| 16 | 2017 | 28 | |
| 17 | 2013 | 77 | |
| 18 | [Clinical efficacy and safety assessment of eribulin monotherapy in patients with metastatic breast cancer - a single- institute experience]. | 2013 | 3 |
| 19 | Chemosterilized autolyzed antigen-extracted allogeneic (AAA) bone matrix gelatin for repair of defects from excision of bone tumors | 1981 | 21 |
| 20 | 3p-B-2 不純物伝導の低温磁化率II | 1979 | 53 |
About Hiroji Iwata
Hiroji Iwata is a scholar working on Oncology, Cancer Research, Pulmonary and Respiratory Medicine, Pathology and Forensic Medicine and Genetics, having authored 520 papers that have together received 23.8k indexed citations. Recurring topics across this work include HER2/EGFR in Cancer Research (165 papers), Advanced Breast Cancer Therapies (155 papers), Breast Cancer Treatment Studies (146 papers), Cancer Treatment and Pharmacology (134 papers), Breast Lesions and Carcinomas (50 papers), Cancer Immunotherapy and Biomarkers (36 papers), Monoclonal and Polyclonal Antibodies Research (35 papers) and Chronic Lymphocytic Leukemia Research (32 papers). The work is most often cited by research in Oncology (16.7k citations), Cancer Research (7.1k citations), Pulmonary and Respiratory Medicine (9.6k citations), Genetics (2.0k citations) and Immunology (2.5k citations). Hiroji Iwata has collaborated with scholars based in Japan, United States and France. Frequent co-authors include Sherene Loi, Hope S. Rugo, Carlos H. Barrios, Seock‐Ah Im, Peter Schmid, Sylvia Adams, Luciana Molinero, Eric P. Winer, Norikazu Masuda and Jane Yuet Ching Hui. Their work appears in journals such as Journal of Clinical Oncology, Breast Cancer, Annals of Oncology, Cancer Research and Breast Cancer Research and Treatment.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.